NRx Pharmaceuticals, Inc. (NRXPW)

US — Healthcare Sector
Peers: NRXP  RLF.SW  QSIAW  EFTRW  RVPHW 

Automate Your Wheel Strategy on NRXPW

With Tiblio's Option Bot, you can configure your own wheel strategy including NRXPW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NRXPW
  • Rev/Share 0.0002
  • Book/Share -1.5333
  • PB -2.1066
  • Debt/Equity 0.0
  • CurrentRatio 0.2216
  • ROIC 0.6499

 

  • MktCap 55844116.0
  • FreeCF/Share -0.694
  • PFCF -4.9033
  • PE -2.1984
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 1.1267

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About NRx Pharmaceuticals, Inc. (NRXPW)

  • IPO Date 2017-12-01
  • Website https://www.nrxpharma.com
  • Industry Biotechnology
  • CEO Dr. Jonathan C. Javitt M.D., M.P.H.
  • Employees None
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.